Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Tuesday broker round-up UPDATE

Tue, 10th Sep 2013 08:17

African Barrick Gold: Investec shifts target price from 135p to 137p, while downgrading from hold to sell.Aquarius Platinum: JP Morgan moves target price from 39p to 49p, while downgrading from neutral to underweight. Citi lowers target price from 66p to 54p and downgrades from buy to neutral.AstraZeneca: Jefferies reduces target price from 3400p to 3200p, while keeping its hold recommendation.Barclays: Alphavalue shifts target price from 342.10p to 341.70p downgrading from buy to add.Betfair: Deutsche Bank raises target price from 884p to 945p staying with its hold recommendation. Citi takes target price from 975p to 1150p and reiterates a buy recommendation.BG Group: Morgan Stanley cuts target price from 1400p to 1370p and retains an overweight rating.Billington Holdings: WH Ireland raises target price from 70p to 125p and maintains a buy recommendation.British Sky Broadcasting: Goldman Sachs ups target price from 1010p to 1170p and reiterates a strong buy recommendation.Centamin: Investec moves target price from 45.60p to 50p keeping its buy recommendation.Craneware: Investec places both its target price (prev.: 365p) and its buy recommendation under review. N+1 Singer downgrades to hold with a target price of 375p.Daily Mail & General Trust: Goldman Sachs raises target price from 695p to 780p, but still recommends selling.Darty: Alphavalue shifts target price from 73.20p to 73.80p and upgrades from sell to reduce.Eland Oil & Gas: Canaccord Genuity lowers target price from 180p to 173p, while leaving its buy recommendation unchanged.Evraz: JP Morgan reduces target price from 252p to 116p keeping its underweight rating.Fenner: Investec ups target price from 330p to 370p and stays with its hold recommendation.GlaxoSmithKline: Jefferies cuts target price from 1825p to 1800p maintaining a hold recommendation.Hilton Food Group: Investec placet both its target price (prev.: 352p) and its add rating under review. Panmure Gordon ups target price from 450p to 480p and keeps a buy recommendation.IGas Energy: Canaccord Genuity moves target price from 174p to 181p retaining a buy recommendation.Intertek Group: Deutsche Bank increases target price from 2820p to 3243p reiterating a hold recommendation.ISG: WH Ireland moves target price from 240p to 250p and reiterates its buy recommendation.Ithaca Energy: Liberum Capital initiates with a target price of 210p and a buy recommendation.Lonmin: JP Morgan takes target price from 330p to 400p and maintains an overweight rating. Citi ups target price from 374p to 418p keeping a buy recommendation.Moneysupermarket: Westhouse Securities downgrades to add with a target price of 195p.Oxford Instruments: Investec ups target price from 1320p to 1500p, while its hold recommendation remains unaltered.Randgold Resources: Investec increases target price from 4981p to 5018p leaving its hold recommendation unchanged.Regus: Panmure Gordon takes target price from 200p to 250p and stays with its buy recommendation.Rio Tinto: JP Morgan raises target price from 4200p to 4300p reiterating an overweight rating.SABMiller: HSBC increases target price from 3400p to 3600p upgrading to overweight.SSE: Morgan Stanley ups target price from 1185p to 1280p, while leaving its underweight rating unchanged.Surgical Innovations: Panmure Gordon shifts target price from 6.60p to 7.60p, while its buy recommendation remains unaltered.Unilever: Deutsche Bank raises target price from 2590p to 2800p upgrading to buy.WPP Group: Goldman Sachs increases target price from 1340p to 1600p and keeps a buy recommendation. Berenberg ups target price from 1050p to 1085p, but still recommends selling.

Related Shares

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.